LPAR1 and fibromyalgia: To pursue the mechanism-based medicine, we have attempted to see involvements of lysophosphatidic acid receptor 1 (LPA1) in various chronic pain models, such as partial sciatic nerve injury-induced (Inoue et al., 2004), paclitaxel-induced (Uchida et al., 2014) and experimental fibromyalgia-like pain models (Ueda and Neyama, 2017), since we have firstly demonstrated LPA1-deficient (LPA1-KO) mice abolish abnormal pain in the partial sciatic nerve ligation (pSNL) model (Inoue et al., 2004).